



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

## Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin Assays: A Practical Approach for Clinicians

**Citation for published version:**

McCarthy, CP, Chapman, A, Sandoval, Y, Apple, FS, Mills, N & Januzzi, JL 2019, 'Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin Assays: A Practical Approach for Clinicians', *JAMA Cardiology*.  
<https://doi.org/10.1001/jamacardio.2019.2724>

**Digital Object Identifier (DOI):**

[10.1001/jamacardio.2019.2724](https://doi.org/10.1001/jamacardio.2019.2724)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

JAMA Cardiology

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# **Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin**

## **Assays: Guide for Clinicians**

Cian P. McCarthy, M.B., B.Ch., B.A.O.<sup>1</sup>; Inbar Raber, M.D.<sup>2</sup>; Andrew R. Chapman, M.D., Ph.D.<sup>3</sup>; Yader Sandoval, M.D.<sup>4</sup>; Fred S. Apple, Ph.D.<sup>5</sup>; Nicholas L. Mills, M.D., Ph.D.<sup>3,6</sup>; James L. Januzzi Jr, M.D.<sup>7,8</sup>.

<sup>1</sup> Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

<sup>2</sup> Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

<sup>3</sup> British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, UK.

<sup>4</sup> Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

<sup>5</sup> Department of Laboratory Medicine and Pathology, Hennepin Healthcare/Hennepin County Medical Center & University of Minnesota, Minneapolis, Minnesota, USA.

<sup>6</sup> Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, UK.

<sup>7</sup> Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA.

<sup>8</sup> Baim Institute for Clinical Research, Boston, Massachusetts, USA.

**Word Count:** 3,490

**Date of Revision:** 5/6/2019

**Corresponding Author:**

James L. Januzzi Jr, MD  
Massachusetts General Hospital  
32 Fruit Street, Yawkey 5B  
Boston, MA, 02114  
P: +1-617-726-3443  
F: +1-617-643-1620  
E: [jjanuzzi@mgh.harvard.edu](mailto:jjanuzzi@mgh.harvard.edu)

**Conflict of Interest Disclosures:**

Dr. Chapman has received honoraria from Abbott Diagnostics and AstraZeneca. Dr. Apple has acted as a consultant for LumiraDx and Banyon Biomarkers, is on the board of directors at HyTest Ltd, has received advisory honoraria from Instrumentation Laboratory and Siemens Healthineers, has been a research principal investigator through the Hennepin Healthcare Research Institute (formerly Minneapolis Medical Research Foundation), and has had non-salaried grant relationships with Abbott Diagnostics, Abbott POC, Roche Diagnostics, Siemens Healthineers, Quidel/Alere, Ortho-Clinical Diagnostics, Qurvo, Becton Dickinson, Beckman Coulter, Amgen, and Singulex. Dr. Mills has acted as a consultant for Abbott Diagnostics, Beckman-Coulter, Roche, and Singulex. Dr. Januzzi has received grant support from Roche Diagnostics, Abbott Diagnostics, Singulex, Prevencio and Cleveland Heart Labs, consulting income from Roche Diagnostics, MyoKardia, Abbott, Critical Diagnostics and participates in clinical endpoint committees/data safety monitoring boards for Boehringer-Ingelheim, Amgen, AbbVie, Janssen, Abbott and Siemens Diagnostics. Dr. Sandoval: present, advisory board, Abbott Diagnostics; past, non-salaried advisory board, Roche Diagnostics. The remaining authors have no conflicts of interest to disclose.

## **Abstract**

**Importance:** Traditionally, elevated troponin concentrations were synonymous with myocardial infarction. However, with improvements in troponin assays, elevated concentrations without overt myocardial ischemia is now more common; an entity referred to as *myocardial injury*. Physicians may be falsely reassured by the absence of myocardial ischemia; however, recent evidence suggests that myocardial injury is associated with even more detrimental outcomes. Accordingly, we review the definition, epidemiology, differential diagnosis, diagnostic evaluation, and management of myocardial injury.

**Observations:** Contemporary epidemiological evidence suggests that myocardial injury (without overt ischemia) represents ~60% of cases of abnormal troponin concentrations when obtained for clinical indications. It is estimated that 1 in 8 patients presenting to the hospital will have evidence of myocardial injury. Myocardial injury pertains a concerning prognosis; 5-year mortality is ~70%, with a major adverse cardiac event rate of 30% over the same period. The differential diagnosis for myocardial injury is broad and can be divided into acute and chronic precipitants. The initial work-up involves an assessment for myocardial ischemia. If infarction is ruled out, further evaluation includes a detailed history, physical examination, laboratory testing, 12-lead electrocardiogram, and if there is no known history of structural or valvular heart disease, an echocardiogram. Unfortunately, no consensus exists regarding routine management of patients with myocardial injury. Identifying and treating the underlying precipitant is the most practical approach.

**Conclusion and Relevance:** Myocardial injury is the most common etiology for abnormal troponin results, and its incidence will likely increase with an aging population, increasing prevalence of cardiovascular comorbidities, and greater sensitivity of troponin assays.

Myocardial injury represents a challenge to clinicians, however given its serious prognosis, it warrants a thorough evaluation for its underlying precipitant. Future strategies to prevent and/or manage myocardial injury are needed.

## Introduction

Cardiac troponin (cTn) was first discovered as a component of the myofibrillar apparatus in 1963.<sup>1</sup> It was, however, a further 30 years before a reliable serum assay for cTn measurement was developed. cTn assays were developed and validated to diagnose acute myocardial infarction (MI) and shown to detect MI with greater accuracy than creatine kinase because of their improved analytical performance, superior analytical sensitivity, and tissue specificity.<sup>2</sup> The majority of cTn in the cardiac myocyte is bound within the sarcomere, while ~5% remains free in the cytoplasm.<sup>3</sup> It is thought that under ischemic conditions, when MI occurs, free cytoplasmic cTn is released first causing an initial rapid change in cTn concentration, while myofibrils are subsequently degraded over several days resulting in a more stable and continuous cTn release.<sup>3</sup> With improvements in technology, cTn can now be quantified above the limit of detection in  $\geq 50\%$  of healthy individuals using high-sensitivity (hs) cTn assays;<sup>4</sup> some pre-clinical assays may reliably detect concentration of cTn in all normal subjects. The mechanism of cTn detection in healthy individuals is not fully understood but hypothesized to be related to myocyte turnover.<sup>5</sup> These advancements in analytical sensitivity have facilitated the early, rapid rule-in and rule-out of MI with ensuing potential to improve patient outcomes and decrease healthcare costs.<sup>6</sup>

The improved analytical sensitivity and the use of the 99<sup>th</sup> percentile upper-reference limit (URL) as the preferred concentration threshold for detecting myocardial injury, however, comes with challenges including increased recognition of cTn concentrations  $>99^{\text{th}}$  percentile without overt myocardial ischemia.<sup>7</sup> This circumstance, termed *myocardial injury*, is now acknowledged in the Fourth Universal Definition of MI as a separate entity.<sup>8</sup> Several studies indicate that using contemporary and hs-assays, myocardial injury in the absence of ischemia is

the most common cause of an increased cTn.<sup>9,10</sup> Accustomed to the connotations that a diagnosis of MI carries, physicians may be falsely reassured by the absence of MI. Myocardial injury, however, is associated with even worse outcomes, with 5-year mortality rates and major adverse cardiovascular events (MACE) of ~70% and ~30% respectively over the same period.<sup>11</sup> Notably, patients with myocardial injury without evidence of infarction, may not necessarily derive benefit from traditional therapies for ischemia.<sup>12,13</sup>

Myocardial injury may be conceptually challenging and its evaluation difficult. While the term myocardial injury applies to any patient with an increased cTn >99<sup>th</sup> percentile (including those with MI), the term is now endorsed as the preferred nomenclature to refer to patients with isolated cTn increases without MI. In this article, the definition, epidemiology, differential diagnosis, and prognosis of myocardial injury are reviewed, after which we provide a practical approach to its evaluation and management.

## **Defining Myocardial Injury**

Myocardial injury is defined as any cTn concentration above the 99<sup>th</sup> percentile URL.<sup>8,14</sup>

Myocardial injury is considered *acute* if there is a rise and/or fall of cTn concentrations exceeding biological and/or analytical variation.<sup>15</sup> No standard exists for how much rise and/or fall of hs-cTn identifies acute injury; typically an increase in the cTn concentration greater than the reference change value (biological variation of an assay) is considered acute for both cTnT and cTnI assays if the initial cTn value is < 99<sup>th</sup> percentile.<sup>14</sup> If the first cTn level is > 99<sup>th</sup> percentile then an increase of at least 50% of the 99<sup>th</sup> percentile or a change > 20% may be considered acute.<sup>14</sup> While small changes in cTn concentration have poor specificity, a large rise and/or fall is much more specific for acute myocardial injury with the largest increases typically

occurring in acute MI (**Figure 1**); the larger the rise and/or fall of cTn, the higher the positive predictive value for MI.<sup>15</sup>

To diagnose any of the five types of MI (**Table 1**), in addition to acute myocardial injury, there must be clinical evidence of acute myocardial ischemia. The diagnosis of myocardial ischemia requires at least one of the following: 1) symptoms of myocardial ischemia, 2) new ischemic electrocardiographic changes, 3) new ischemic regional wall motion abnormalities on cardiac imaging, or 4) acute coronary thrombus on coronary angiography.<sup>8</sup> In the absence of these pre-requisites, MI cannot be diagnosed. Differentiating type 2 MI from myocardial injury can be particularly challenging. Both entities can have overlapping precipitants [e.g. heart failure (HF) and sepsis] but they are differentiated by the presence of ischemia which is needed to diagnose type 2 MI.<sup>8</sup> However, evaluating for the presence of ischemia can be challenging in certain situations such as the intubated patient or when atypical symptoms exist.

At lower cTn concentrations, which are the most often frequently encountered in clinical practice; besides ischemic mechanisms leading to acute MI, several other mechanisms of acute myocardial injury have been described, including those that cause increase cTn release such as myocardial strain,<sup>16</sup> inflammation,<sup>17</sup> apoptosis,<sup>16</sup> and cell injury,<sup>18</sup> or those that decrease cTn clearance such as acute or chronic kidney injury (**Figure 2**);<sup>19</sup> all must be considered in the differential diagnosis if the presentation is ambiguous.

A cTn result above the 99<sup>th</sup> percentile URL without a rise and/or fall over a period of serial measurements (e.g. over 8 hours) is characteristic of *chronic* myocardial injury in the appropriate clinical setting.

## **Epidemiology**

The reported incidence of myocardial injury has varied according to the setting in which the cTn was measured (**Table 2**). In a cohort of 918 consecutive patients presenting to the emergency department (ED) *without* symptoms of MI, the incidence of myocardial injury was 12% (of which 4% of patients were had MI).<sup>20</sup> Predictably, among patients presenting to the ED with suspicion of MI the incidence of myocardial injury is higher. In the Use of TROPonin In Acute coronary syndrome (UTROPIA) study, a prospective observational study of 1,640 ED patients undergoing serial hs-cTnI (Abbott) measurements on clinical indication, Sandoval and colleagues found that 26% of patients had at least one cTnI >99<sup>th</sup> percentile, of which 58% were determined to be myocardial injury.<sup>9</sup> The investigators found that the most frequent etiologies of myocardial injury were renal failure, HF, and neurological conditions.<sup>9</sup> The High-Sensitivity Troponin in the Evaluation of patients with suspected Acute Coronary Syndrome (High-STEACS) trial was a stepped-wedge, cluster-randomized controlled trial that prospectively evaluated the implementation of a hs-cTnI assay among 48,282 consecutive patients presenting with suspected MI to ten hospitals in Scotland.<sup>21</sup> The investigators found the incidence of myocardial injury to be 21%, of which 69% were diagnosed with MI. Notably, few epidemiological studies to date have differentiated acute from chronic myocardial injury. Examining 39,558 patients presenting to the ED with chest pain, Kadesjo and colleagues found that 3,855 patients had a hs-cTn concentration greater than the 99<sup>th</sup> percentile. Of these, 29% had type 1 MI, 6.5% had type 2 MI, 29.5% had acute myocardial injury, and the majority (35%) had chronic myocardial injury.<sup>22</sup>

In the current era of hs-assays, myocardial injury may now be the most common cause of increased cTn when examined in hospitalized patients. Using the Veterans Affairs centralized databases, McFalls *et al.* identified patients hospitalized with increased cTn concentrations in

2006.<sup>10</sup> Among 100, 433 patients who had a troponin (cTnT or cTnI) measured during their index admission, 24% were diagnosed with myocardial injury; the majority (57%) were not found to have MI.<sup>10</sup> Of the patients with non-infarction cTn increases, more than 40% carried a primary diagnosis of cardiac origin, such as HF and chronic coronary artery disease (CAD), while others were diagnosed with infections or diseases related to the renal, gastrointestinal, and neurologic systems.<sup>10</sup> Similarly, examining 3,762 patients with hs-cTnI measured during index hospitalization, Sarkisian *et al.* found the incidence of myocardial injury to be 42% and only 31% of these patients were diagnosed with MI.<sup>23</sup> Dolci *et al.* found the incidence of ischemic and non-ischemic myocardial injury among hospitalized patients to be slightly higher at 59%.<sup>24</sup>

## **Differential Diagnosis**

The differential diagnosis for myocardial injury is broad and can be divided into acute or chronic causes (**Figures 1 and 2**).

### *Acute Myocardial Injury*

When a rise and/or fall of cTn with at least one concentration >99<sup>th</sup> percentile URL is encountered, acute MI is a primary consideration; the larger the magnitude of the cTn increase, the more likely acute MI is the cause. That said, even when faced with moderate degrees of injury, a broad range of precipitants of myocardial injury should be considered. *Cardiovascular* causes of acute myocardial injury include MI,<sup>8</sup> pulmonary embolism (PE),<sup>25</sup> myocarditis,<sup>17</sup> and/or myopericarditis,<sup>26</sup> aortic dissection,<sup>27</sup> cardiac surgery,<sup>28</sup> or procedures<sup>29</sup> (e.g. cardioversion or ablation), hypertension,<sup>16</sup> arrhythmias,<sup>30</sup> acute HF,<sup>31</sup> acute valvular heart disease<sup>32</sup> (e.g.: aortic regurgitation or mitral regurgitation), Takotsubo cardiomyopathy,<sup>33</sup> and cardiac contusions<sup>34</sup> (including chest compressions). If accompanying clinical evidence of acute

myocardial ischemia is identified, then acute MI should be diagnosed. For example, in the absence of overt myocardial ischemia, most patients with acute HF should be categorized as having myocardial injury; however, acute HF can occur due to myocardial ischemia, and when these patients are identified to have clinical evidence of myocardial ischemia, then acute MI is diagnosed. *Non-cardiovascular* causes and/or triggers of myocardial injury include acute renal failure,<sup>35</sup> sepsis,<sup>36</sup> anemia,<sup>37</sup> hypotension,<sup>38</sup> hypoxia,<sup>39</sup> non-cardiac surgery,<sup>40</sup> critical illness,<sup>41</sup> rhabdomyolysis,<sup>42</sup> drug induced (e.g. chemotherapy),<sup>18</sup> stroke,<sup>43</sup> and extreme exertion.<sup>44</sup> A common vexing issue is the effect of renal dysfunction on cTn concentrations. One prevalent hypothesis is that myocardial injury in patients with advanced kidney disease is a consequence of decreased clearance of cardiac troponin. However, its presence is likely multifactorial and also influenced by other factors such as underlying CAD,<sup>45</sup> and left ventricular mass.<sup>19</sup>

### Chronic Myocardial Injury

*Cardiovascular* causes of chronic myocardial injury include chronic HF,<sup>46</sup> infiltrative cardiomyopathies<sup>47</sup> (amyloidosis, hemochromatosis, and sarcoidosis), hypertrophic cardiomyopathy,<sup>48</sup> stable CAD,<sup>49</sup> hypertension,<sup>50</sup> valvular heart disease,<sup>51</sup> and persistent arrhythmias (e.g. atrial fibrillation).<sup>52</sup> *Non-cardiovascular* causes include chronic renal disease,<sup>53</sup> pulmonary hypertension,<sup>54</sup> toxins,<sup>55</sup> and diabetes mellitus.<sup>56</sup>

## **Prognosis**

Emerging evidence from several observational studies indicates that myocardial injury pertains a concerning prognosis (**Figure 3**). Most studies have not delineated acute versus chronic myocardial injury without infarction, and there remains limited data on differences in outcomes between these two entities.

One small retrospective study showed that patients with non-cardiac precipitating factors for their increased cTnI at presentation have higher in-hospital mortality (26.7% vs. 13.4%,  $p=0.002$ ) compared to cardiac-related precipitants.<sup>57</sup> Beyond the initial hospitalization, myocardial injury has high short term mortality; 11% at 6 months and 26% at 2-years.<sup>9</sup> Age, maximum cTnI concentration, and a history of HF were predictive of 2-year mortality.<sup>9</sup> Longer term outcomes were examined by Chapman and colleagues, who found that 5-year mortality was as high as 72%.<sup>11</sup> The long-term mortality from myocardial injury was mostly driven from non-cardiovascular causes (62%).<sup>11</sup> Accordingly, some of this mortality risk may not be modifiable. Cardiovascular event rates, however, are also high among this population. The 5-year MACE rates were 31% with 28% of patients experiencing a cardiovascular death.<sup>11</sup> Over 5-years, 4.8% of patients with myocardial injury experience a non-fatal MI, 5.6% a HF hospitalization, and 3.9% a stroke.<sup>11</sup> Patients with myocardial injury in the absence of MI, had a higher risk of all-cause mortality compared to type 1 MI (adjusted relative risk: 2.09; 95% confidence interval, 1.72-2.55) but a lower risk of MACE (adjusted relative risk 0.77 95% confidence interval, 0.66-0.89). A large retrospective analysis of 9,800 patients with myocardial injury without MI, diagnosed by either conventional or hs-cTn, included in the SWEDEHEART registry (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) found similarly morbid long term outcomes; with 15.4% of patients having MACE (composite of all-cause mortality, MI, readmission for HF, or stroke at a median follow-up 4.9 years). Furthermore, they reported that the magnitude of myocardial injury was an important predictor of mortality, with successive increases in hazard ratios across troponin tertiles, even when adjusting for presence of cardiovascular disease or prevalent comorbidities.<sup>58</sup> Examining outcomes among patients with myocardial injury

diagnosed in the ED, Kadesjo *et al.* found that patients with acute myocardial injury had a 21% higher risk of all-cause mortality and a 30% higher risk of HF compared to patients with chronic myocardial injury over a median follow-up of 3.9 years.<sup>22</sup>

Myocardial injury occurs in a heterogeneous group of patients; consisting of both cardiac and non-cardiac types of insult; which likely confer different prognostic implications. A prospective study on patients with myocardial injury categorized patients based on etiology: ischemic, non-ischemic cardiac (e.g. major cardiac surgery), noncardiac (e.g. infection) or multifactorial (at least 2 cardiac or non-cardiac conditions) conditions.<sup>59</sup> Researchers found that after adjusting for covariates, cardiac ischemic and non-ischemic patients had similar mortality rates. However, diagnoses of noncardiac and multifactorial causes of myocardial injury carried higher mortality compared to cardiac ischemic types of injury (hazard ratio 1.39, 95% confidence interval 1.06-1.80;  $p = 0.02$ ).<sup>59</sup> Patients with chronic HF often have evidence of myocardial injury and a meta-analysis of 9,289 patients found that cTn increases predicted all-cause mortality (hazard ratio (HR) 1.48,  $p < 0.001$ ), cardiovascular death (HR 1.40,  $p < 0.001$ ), and cardiovascular hospitalization (HR 1.42,  $p < 0.001$ ).<sup>46</sup>

Troponin levels may correlate with clinical prognosis in some cases. Increases in cTnI concentrations in patients undergoing high dose chemotherapy for aggressive malignancies have been correlated with future reductions in left ventricular ejection fraction.<sup>60</sup> In patients with chronic kidney disease and end-stage renal disease, increased cTn concentrations are associated with higher rates of all-cause mortality.<sup>61,62</sup> In patients with amyloidosis<sup>47</sup> or pulmonary embolism,<sup>63</sup> detection of cTn were found to be strong predictors of all-cause mortality. Troponin detection can also be induced by exercise, though the clinical implication of the cTn elevation not well understood.<sup>44</sup> Prognostication using cTn certainly does not apply for all causes of

myocardial injury nor would peak cTn level necessarily enable prognostication across various causes of myocardial injury, which can cause vastly different levels of cTn elevation.

Risk stratification for patients with myocardial injury and identification of patients would benefit from close monitoring and further testing is an area of ongoing investigation, especially given the evidence that increased cTn concentrations carry prognostic significance. Risk stratification may guide frequency of follow-up visits post-discharge facilitating surveillance for symptoms of ischemia, HF, and optimization of preventative therapies. The TARRACO (Troponin Assessment for Risk stratification of patients without Acute COronary atherosclerosis) risk score was recently developed to risk stratify patients with type 2 MI or myocardial injury and externally validated in a cohort of 401 patients.<sup>64</sup> The score combines cTn concentrations and predictors of adverse cardiovascular events in this population, including age, hypertension, absence of chest pain, dyspnea, and anemia. MACE events were five times higher in the high-risk patients compared to the lowest risk patients based on this score.<sup>64</sup> The utility of this score to alter the prognosis of patients (by guiding further investigation or therapeutic intervention) will however need evaluation in a clinical trial.

Taken together, these trends in morbidity and mortality underscore the reality that myocardial injury with 'negative' ischemic work-up does not offer reassurance; rather, a careful evaluation for alternate etiologies should be considered. Furthermore, trivializing such circumstances as a "troponin leak" or "troponinemia" is strongly discouraged. Although prospective studies are needed to demonstrate that outcomes for patients with myocardial injury are indeed modifiable, the consistency of the evidence that myocardial injury is associated with very poor outcomes across a broad range of healthcare settings requires clinicians to take elevated troponin seriously.

## **Evaluating Myocardial Injury**

The initial assessment of myocardial injury focuses on the 1) assessment of ischemic symptoms, 2) review of the patient's past medical history and cardiovascular risk factors, 3) serial 12-lead electrocardiograms, 4) serial cTn measurements assessed over 3-12 hour periods depending on sensitivity of the assay, 5) imaging: an echocardiogram to assess for regional wall motion abnormalities and exclude the presence of cardiomyopathy and/or structural heart disease, and/or 6) coronary angiography (computerized tomography or invasive).

If the patient reports symptoms of angina—even atypical—they nominally meet the Universal Definition for acute MI, and an ischemic evaluation should be undertaken, if not previously performed. If myocardial infarction is excluded the subsequent assessment includes a comprehensive history and physical examination, laboratory testing, and where appropriate, cardiac imaging.

### *History and Physical Examination*

Inquiring about the presence and nature of chest discomfort is important. Pleuritic discomfort may suggest PE, pneumonia, or myocarditis. Discomfort radiating to the back may suggest aortic dissection. Symptoms suggestive of HF (dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and peripheral edema), valvular heart disease (syncope, angina, and dyspnea), cardiac arrhythmias (palpitations), and infections (fevers, chills) should be explored. Recent procedures (cardiac and non-cardiac), use of cardiotoxic medications (in particular chemotherapy and substance abuse), activity (intense exercise regimens), life stressors (Takotsubo cardiomyopathy), recent travel, and past medical history (specifically cardiovascular, pulmonary, and renal comorbidities) should be reviewed.

The physical examination must include an appraisal of the patients' vital signs, cardiovascular system (heart rate and rhythm, murmurs, presence of congestion), pulmonary system (wheezing, rhonchi, and crackles), and potential sources of infection.

### Laboratory Data and Imaging

Serial cTn measurements are informative to differentiate acute from chronic myocardial injury; when using hs-cTn assays. In early and late presenters or in those in whom symptom onset is uncertain and distinguishing acute vs. chronic injury from infarction remains uncertain, a 3<sup>rd</sup> sample can be helpful as up to 26% of patients with acute MI may not demonstrate a significant rise and/or fall.<sup>65</sup> A 12-lead electrocardiogram should be obtained at presentation and reviewed for signs of ischemia/infarction, arrhythmias, acute right ventricular strain, and signs of conduction or structural disease (e.g. left ventricular hypertrophy). We recommend assessment of renal function and measurement of a natriuretic peptide to provide complementary information regarding common causes of non-MI related injury, such as chronic kidney disease or HF, respectively). A complete blood count (anemia or infection) should be attained. Additional laboratory testing such as d-dimer (considering PE and aortic dissection), and infectious/inflammatory markers (e.g. c-reactive protein) can be guided by clinical assessment. An echocardiogram should be obtained to assess for systolic or diastolic dysfunction, left ventricular hypertrophy, wall motion abnormalities, or valvular abnormalities. Further imaging such as cardiac magnetic resonance imaging may be obtained depending on the clinical scenario (e.g. suspected myocarditis or infiltrative cardiomyopathy).

## **Treatment**

For type 1 MI, an evidence-based treatment is well established.<sup>66,67</sup> For type 2 MI, present recommendations are to individualize care and correct the supply/demand alteration (e.g.: anemia, tachycardia, hypotension, etc.) leading to myocardial ischemia. The DETERMINING the MECHANISM of myocardial injury AND role of coronary disease in type 2 Myocardial Infarction (DEMAND MI; NCT03338504) trial is attempting to improve our understanding of the mechanisms of ischemic myocardial injury by engaging computed tomography coronary angiography, invasive coronary angiography, and cardiac magnetic resonance imaging. The Appropriateness of Coronary investigation in myocardial injury and Type 2 myocardial infarction (ACT-2) trial is randomizing 300 patients with myocardial injury to invasive angiography (or computed tomography angiography) within 5 days of randomization versus conservative management (with or without functional testing at clinician discretion) with a primary endpoint of all-cause mortality at 2 years.<sup>68</sup> Cost-effectiveness will be determined based on clinical events, quality of life, and resource utilization over 24 months.<sup>68</sup>

Beyond those patients with ischemic myocardial injury, unfortunately, no consensus exists regarding routine management of patients with myocardial injury. The management of myocardial injury may thus focus on the identification and treatment of the underlying precipitant (e.g. HF).

Whether therapies to attenuate injury itself are of benefit remains unclear and data are largely retrospective and/or inconclusive. The WOSCOPS (West of Scotland Coronary Prevention Study) investigators found pravastatin reduced hs-cTnI concentrations in an ambulatory population free of prior MI by an average of 13%, and change in troponin at 1-year was associated with future MI risk reduction independent of cholesterol lowering.<sup>69</sup> However, this was a primary prevention study, and the applicability of these findings to patients

with acute non-ischemic myocardial injury is uncertain. The MANAGE (Management of Myocardial Injury After Noncardiac Surgery) trial found that dabigatran lowered major vascular event rates when compared with placebo (11% versus 15%,  $p=0.02$ ) among patients with myocardial injury after noncardiac surgery.<sup>70</sup> Nonetheless, the results of this trial should be interpreted cautiously as the trial was terminated early and medication discontinuation rates were high. Further, given the heterogeneity in etiologies, it is difficult to conceive that one-single approach can be used for all patients and the primary composite endpoint was broad (vascular mortality, non-fatal MI, non-hemorrhagic stroke, peripheral arterial thrombosis, amputation, and symptomatic venous thromboembolism). Lastly, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to enhance diuresis, reduce blood pressure, and improve left ventricular remodeling.<sup>71</sup> In patients with diabetes mellitus, canagliflozin delayed a rise in troponin over 2-years when compared to placebo.<sup>72</sup> Thus, these agents, along with others with alter hemodynamic stress, warrant investigation among patients with myocardial injury.

## **Conclusion**

The 4th Universal Definition of MI recently considered the phenomenon of myocardial injury as a separate, unique entity. Myocardial injury is the most common etiology for abnormal hs-cTn results, and its incidence will likely increase with an aging population, increasing prevalence of cardiovascular comorbidities, and greater sensitivity of hs-cTn assays. Myocardial injury represents a challenge to clinicians, however given its serious prognosis, it warrants a thorough evaluation for its underlying precipitant. Future strategies to prevent and/or manage myocardial injury are needed.

## References

1. Ebashi S. Third Component Participating in the Super precipitation of 'Natural Actomyosin'. *Nature*. 1963;200:1010.
2. Wu AH, Feng YJ, Contois JH, Pervaiz S. Comparison of myoglobin, creatine kinase-MB, and cardiac troponin I for diagnosis of acute myocardial infarction. *Ann Clin Lab Sci*. 1996;26(4):291-300.
3. Katus HA, Remppis A, Scheffold T, Diederich KW, Kuebler W. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. *Am J Cardiol*. 1991;67(16):1360-1367.
4. Apple FS, Sandoval Y, Jaffe AS, Ordóñez-Llanos J. Cardiac Troponin Assays: Guide to Understanding Analytical Characteristics and Their Impact on Clinical Care. *Clin Chem*. 2017;63(1):73-81.
5. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. *Science*. 2009;324(5923):98-102.
6. Keller T, Zeller T, Ojeda F, et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. *JAMA*. 2011;306(24):2684-2693.
7. Sandoval Y, Thygesen K. Myocardial Infarction Type 2 and Myocardial Injury. *Clin Chem*. 2017;63(1):101-107.
8. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). *J Am Coll Cardiol*. 2018;72(18):2231-2264
9. Sandoval Y, Smith SW, Sexter A, et al. Type 1 and 2 Myocardial Infarction and Myocardial Injury: Clinical Transition to High-Sensitivity Cardiac Troponin I. *Am J Med*. 2017;130(12):1431-1439.e1434.
10. McFalls EO, Larsen G, Johnson GR, et al. Outcomes of hospitalized patients with non-acute coronary syndrome and elevated cardiac troponin level. *Am J Med*. 2011;124(7):630-635.
11. Chapman AR, Shah ASV, Lee KK, et al. Long-Term Outcomes in Patients With Type 2 Myocardial Infarction and Myocardial Injury. *Circulation*. 2018;137(12):1236-1245.
12. Everett BM, Brooks MM, Vlachos HEA, et al. Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. *N Engl J Med*. 2015;373(7):610-620.
13. Omland T, Pfeffer MA, Solomon SD, et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. *J Am Coll Cardiol*. 2013;61(12):1240-1249.
14. Wu AHB, Christenson RH, Greene DN, et al. Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. *Clin Chem*. 2018;64(4):645-655.
15. Twerenbold R, Jaffe A, Reichlin T, Reiter M, Mueller C. High-sensitive troponin T measurements: what do we gain and what are the challenges? *Eur Heart J*. 2012;33(5):579-586.

16. Weil BR, Suzuki G, Young RF, Iyer V, Canty JM. Troponin Release and Reversible Left Ventricular Dysfunction After Transient Pressure Overload. *J Am Coll Cardiol.* 2018;71(25):2906-2916.
17. Lauer B, Niederau C, Kuhl U, et al. Cardiac troponin T in patients with clinically suspected myocarditis. *J Am Coll Cardiol.* 1997;30(5):1354-1359.
18. Kitayama H, Kondo T, Sugiyama J, et al. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. *Breast Cancer.* 2017;24(6):774-782.
19. deFilippi C, Seliger SL, Kelley W, et al. Interpreting Cardiac Troponin Results from High-Sensitivity Assays in Chronic Kidney Disease without Acute Coronary Syndrome. *Clin Chem.* 2012;58(9):1342-1351.
20. Lee KK, Noaman A, Vaswani A, et al. Prevalence, Determinants, and Clinical Associations of High-Sensitivity Cardiac Troponin in Patients Attending Emergency Departments. *Am J Med.* 2019;132(1):110.e118-110.e121.
21. Shah ASV, Anand A, Strachan FE, et al. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. *Lancet.* 2018;392(10151):919-928.
22. Kadesjo E, Roos A, Siddiqui AJ, Desta L, Lundback M, Holzmann M. Acute versus Chronic Myocardial Injury and Outcomes. *J Am Coll Cardiol.* 2019;73(9 Supplement 1):105.
23. Sarkisian L, Saaby L, Poulsen TS, et al. Clinical Characteristics and Outcomes of Patients with Myocardial Infarction, Myocardial Injury, and Nonelevated Troponins. *Am J Med.* 2016;129(4):446.e445-446.e421.
24. Dolci A, Braga F, Valente C, Guzzetti S, Panteghini M. Impact of implementation of the high-sensitivity cardiac troponin T assay in a university hospital setting. *Clin Chem.* 2011;57(8):1211-1212.
25. Ginsberg JDD, Mark AC, Eric BS, Jeffrey S. Elevated Cardiac Troponin Levels in Patients With Submassive Pulmonary Embolism. *Arch Intern Med.* 2019;162(1):79-81.
26. Kobayashi D, Aggarwal S, Kheiwa A, Shah N. Myopericarditis in children: elevated troponin I level does not predict outcome. *Pediatr Cardiol.* 2012;33(7):1040-1045.
27. Vagnarelli F, Corsinia A, Bugani G et al. Troponin T elevation in acute aortic syndromes: Frequency and impact on diagnostic delay and misdiagnosis. *Eur Heart J Acute Cardiovasc Care.* 2016;5(7):61-71
28. Januzzi JL, Lewandrowski K, MacGillivray TE, et al. A comparison of cardiac troponin T and creatine kinase-MB for patient evaluation after cardiac surgery. *J Am Coll Cardiol.* 2002;39(9):1518-1523.
29. Yoshida K, Yui Y, Kimata A, et al. Troponin elevation after radiofrequency catheter ablation of atrial fibrillation: relevance to AF substrate, procedural outcomes, and reverse structural remodeling. *Heart Rhythm.* 2014;11(8):1336-1342.
30. Thelin J, Melander O. Dynamic high-sensitivity troponin elevations in atrial fibrillation patients might not be associated with significant coronary artery disease. *BMC Cardiovasc Disord.* 2017;17(1):169
31. Peacock WF 4th, De Marco T, Fonarow GC, et al. Cardiac Troponin and Outcome in Acute Heart Failure. *N Engl J Med.* 2008;358(20):2117-26.

32. Olaf S, Debora B, Ricarda B, et al. Exercise tolerance in asymptomatic patients with moderate-severe valvular heart disease and preserved ejection fraction. *Arch Med Sci.* 2012;8(6):1018-1026.
33. Madhavan M, Borlaug BA, Lerma A, Rihal CS, Prasad A. Stress hormone and circulating biomarker profile of apical ballooning syndrome (Takotsubo cardiomyopathy): insights into the clinical significance of B-type natriuretic peptide and troponin levels. *Heart.* 2009;95(17):1436-41
34. Mullner M, Oschatz E, Sterz F, et al. The influence of chest compressions and external defibrillation on the release of creatine kinase-MB and cardiac troponin T in patients resuscitated from out-of-hospital cardiac arrest. *Resuscitation.* 1998;38(2):99-105.
35. Song D, de Zoysa JR, Ng A, Chiu W. Troponins in acute kidney injury. *Ren Fail.* 2012;34(1):35-39.
36. Ammann P, Fehr T, Minder EI, Gunter C, Bertel O. Elevation of troponin I in sepsis and septic shock. *Intensive Care Med.* 2001;27(6):965-969.
37. Bellotto F, Fagioli S, Pavei A, et al. Anemia and ischemia: Myocardial injury in patients with gastrointestinal bleeding. *Am J Med.* 2005;118(5):548-551.
38. Klein Gunnewiek JMT, van de Leur J. Elevated troponin T concentrations in critically ill patients. *Intensive Care Med.* 2003;29(12):2317-2322.
39. Brekke PH, Omland T, Holmedal SH, Smith P, Soyseth V. Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. *Eur Respir J.* 2008;31(3):563-70.
40. Puelacher C, Lurati Buse G, Seeberger D, et al. Perioperative Myocardial Injury After Noncardiac Surgery: Incidence, Mortality, and Characterization. *Circulation.* 2018;137(12):1221-1232.
41. Cook WL, Ismael Q, Devereaux PJ, et al. Elevated Cardiac Troponin Measurements in Critically Ill Patients. *Arch Intern Med.* 2019;166(22):2446-2454.
42. Pudukollu G, Gowda RM, Khan IA, et al. Elevated serum cardiac troponin I in rhabdomyolysis. *Int J Cardiol.* 2004;96(1):35-40.
43. Sandhu R, Aronow WS, Rajdev A, et al. Relation of cardiac troponin I levels with in-hospital mortality in patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. *Am J Cardiol.* 2008;102(5):632-634.
44. Fortescue EB, Shin AY, Greenes DS, et al. Cardiac troponin increases among runners in the Boston Marathon. *Ann Emerg Med.* 2007;49(2):137-143, 143.e131.
45. deFilippi C, Wasserman S, Rosanio S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. *JAMA.* 2003;290(3):353-359.
46. Aimo A, Januzzi JL, Jr., Vergaro G, et al. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. *Circulation.* 2018;137(3):286-297.
47. Qian G, Wu C, Zhang Y, Chen YD, Dong W, Ren YH. Prognostic value of high-sensitivity cardiac troponin T in patients with endomyocardial-biopsy proven cardiac amyloidosis. *J Geriatr Cardiol.* Vol 112014:136-140.
48. Kubo T, Kitaoka H, Yamanaka S, et al. Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. *J Am Coll Cardiol.* 2013;62(14):1252-1259.

49. Januzzi JL, Jr., Suchindran S, Coles A, et al. High-Sensitivity Troponin I and Coronary Computed Tomography in Symptomatic Outpatients With Suspected Coronary Artery Disease: Insights From the PROMISE Trial. *JACC Cardiovasc Imaging*. 2018 (In press).
50. Aeschbacher S, Schoen T, Bossard M, et al. Relationship between high-sensitivity cardiac troponin I and blood pressure among young and healthy adults. *Am J Hypertens*. 2015;28(6):789-796.
51. Rosjo H, Andreassen J, Edvardsen T, Omland T. Prognostic usefulness of circulating high-sensitivity troponin T in aortic stenosis and relation to echocardiographic indexes of cardiac function and anatomy. *Am J Cardiol*. 2011;108(1):88-91.
52. van den Bos EJ, Constantinescu AA, van Domburg RT, Akin S, Jordaens LJ, Kofflard MJ. Minor elevations in troponin I are associated with mortality and adverse cardiac events in patients with atrial fibrillation. *Eur Heart J*. 2011;32(5):611-617.
53. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. *Circulation*. 2002;106(23):2941-2945.
54. Heresi GA, Tang WH, AYTEKIN M, Hammel J, Hazen SL, Dweik RA. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. *Eur Respir J*. 2012;39(4):939-944.
55. Riley ED, Hsue PY, Vittinghoff E, et al. Higher prevalence of detectable troponin I among cocaine-users without known cardiovascular disease. *Drug Alcohol Depend*. 2017;172:88-93.
56. Carvalho, Raul Cavalcante M, José Antonio Franchini R, et al. Troponin in diabetic patients with and without chronic coronary artery disease. *BMC Cardiovasc Disord*. 2015;15(1):72.
57. Ilva TJ, Eskola MJ, Nikus KC, et al. The etiology and prognostic significance of cardiac troponin I elevation in unselected emergency department patients. *J Emerg Med*. 2010;38(1):1-5.
58. Eggers KM, Jernberg T, Lindahl B. Cardiac Troponin Elevation in Patients Without a Specific Diagnosis. *J Am Coll Cardiol*. 2019;73(1):1-9.
59. Sarkisian L, Saaby L, Poulsen TS, et al. Prognostic Impact of Myocardial Injury Related to Various Cardiac and Noncardiac Conditions. *Am J Med*. 2016;129(5):506-514.e501.
60. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. *J Am Coll Cardiol*. 2000;36(2):517-522.
61. Michos ED, Wilson LM, Yeh HC, et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta-analysis. *Ann Intern Med*. 2014;161(7):491-501.
62. Sandoval Y, Herzog CA, Love SA, et al. Prognostic Value of Serial Changes in High-Sensitivity Cardiac Troponin I and T over 3 Months Using Reference Change Values in Hemodialysis Patients. *Clin Chem*. 2016;62(4):631-638.
63. La Vecchia L, Ottani F, Favero L, et al. Increased cardiac troponin I on admission predicts in-hospital mortality in acute pulmonary embolism. *Heart*. 2014;90(6):633-7.
64. Cedié G, Sandoval Y, Sexter A, et al. Risk Estimation in Type 2 Myocardial Infarction and Myocardial Injury: The TARRACO Risk Score. *Am J Med*. 2018;132(2):217-226.

65. Bjurman C, Larsson M, Johanson P, et al. Small changes in troponin T levels are common in patients with non-ST-segment elevation myocardial infarction and are linked to higher mortality. *J Am Coll Cardiol*. 2013;62(14):1231-1238.
66. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013;61(4):e78-e140.
67. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. *Circulation*. 2014;130(25):e344-e426.
68. Lambrakis K, French JK, Scott IA, et al. The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design. *Am Heart J*. 2018;208:11-20.
69. Ford I, Shah ASV, Zhang R, et al. High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease. *J Am Coll Cardiol*. 2016;68(25):2719-2728.
70. Devereaux PJ, Duceppe E, Guyatt G, et al. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. *Lancet*. 2018;391(10137):2325-2334.
71. Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. *J Am Coll Cardiol*. 2019;73(15):1931-1944.
72. Januzzi JL, Jr., Butler J, Jarolim P, et al. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. *J Am Coll Cardiol*. 2017;70(6):704-712.

## Figure Legends

**Figure 1:** Figure illustrating most likely causes of myocardial injury stratified by cardiac troponin concentration. Abbreviations: HF= heart failure, LVH= left ventricular hypertrophy, MI= myocardial infarction, PE= pulmonary embolism. Taken with permission from Januzzi JL Jr et al; Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel. *JACC*:2019;73(9):1059-1077.

**Figure 2:** Figure illustrating the evaluation, differential diagnosis, and approach to management of acute and chronic myocardial injury. Abbreviations: ECG= electrocardiogram, PCI= percutaneous coronary intervention, TTE= transthoracic echocardiogram.

**Figure 3:** Multivariable-adjusted hazard ratios (with 95% CIs) of major adverse events in patients with troponin elevation without specific diagnosis and in subcohorts. In all cohorts, the risk of major adverse events increased in a stepwise fashion across higher assay-specific cardiac troponin (cTn) levels, with patients in the highest tertile being at particularly high risk. Patients with cTn  $\leq$ 99th percentile were used as reference group. All analyses are adjusted for age, sex, admission year, hospital, and cTn assay. CABG = coronary artery bypass grafting; CI = confidence interval; cTn = cardiac troponin; eGFR = estimated glomerular filtration rate; HR = hazard ratio; LVEF = left ventricular ejection fraction; MI = myocardial infarction; PCI = percutaneous coronary intervention. Taken with permission from Eggers et al; Cardiac troponin Elevation in Patients Without Specific Diagnosis. *JACC*:2019;73:1-9.

**Table 1:** Definitions of Acute and Chronic Myocardial Injury and the Subtypes of Myocardial Infarction

<b>Myocardial Injury</b>	<i>Troponin concentration above the 99<sup>th</sup> percentile URL, regardless of cause</i>	
	<b>Acute</b>	Dynamic rise and/or fall of troponin concentration due to cardiovascular or non-cardiovascular causes
	<b>Chronic</b>	Persistently elevated troponin concentration due to cardiovascular or non-cardiovascular causes
<b>Myocardial Infarction</b>	<i>Dynamic rise or fall of troponin concentration above 99<sup>th</sup> percentile URL with myocardial ischemia evidenced by 1) symptoms of ischemia, 2) new ischemic electrocardiographic findings, 3) new ischemic wall motion abnormalities on echocardiogram, 4) coronary thrombus visualized on coronary angiography</i>	
	<b>Type 1</b>	Myocardial infarction caused by plaque rupture, ulceration, or dissection
	<b>Type 2</b>	Myocardial infarction due to oxygen supply-demand mismatch
	<b>Type 3</b>	Sudden cardiac death with etiology most likely myocardial infarction
	<b>Type 4</b>	Myocardial infarction associated with percutaneous intervention or stent thrombosis
	<b>Type 5</b>	Myocardial infarction associated with cardiac surgery

**Table 2:** Table showing studies which report detection of myocardial injury in various settings.

Abbreviations: ACS=acute coronary syndrome, cTn= cardiac troponin, ED= emergency

department, hs-cTn=high sensitivity troponin, MI=myocardial infarction, VA=veterans affairs.

Study	Setting	Location	Assay	Incidence of Myocardial injury	Cause of myocardial injury	Reference
Lee <i>et al.</i>	918 consecutive patients presenting to the ED <i>without</i> symptoms of ACS	Scotland	Hs-cTnI (Abbott)	12%	- Non-ischemic myocardial injury= 96%.  - MI= 4%.	<sup>20</sup>
Sandoval <i>et al.</i>	1,640 patients presenting to the ED for suspicion of ACS	United States	Hs-cTnI (Abbott)	26%	- Non-ischemic myocardial injury= 58%  - MI= 42%	<sup>9</sup>
Shah <i>et al.</i>	48,282 patients presenting to the ED for suspicion of ACS	Scotland	Hs-cTnI (Abbott)	21%	- Non-ischemic myocardial injury= 31%  - MI= 69%	<sup>21</sup>
Kadesjo <i>et al.</i>	39,558 patients presenting to the ED for suspicion of ACS	Sweden	Hs-cTnT	10%	- Non-ischemic myocardial injury 64.5% (29.5% acute injury and 35% chronic injury)  - MI= 35.5%	<sup>22</sup>
Sarkisian <i>et al.</i>	3,762 patients with hs-cTn measured during	Denmark	Hs-cTnI (Abbott)	42%	- Non-ischemic myocardial injury= 69%	<sup>23</sup>

	their hospitalization.				- MI= 31%	
Dolci <i>et al.</i>	1,137 patients with hs-cTn measured during their hospitalization.	Italy	Hs-cTnT (Roche).	59%	Not provided	<sup>24</sup>
McFall <i>et al.</i>	100, 433 VA patients with cTn measured during their index admission	United States	cTnI and cTnT	24%	- Non-ischemic myocardial injury= 57% - MI= 43%	<sup>10</sup>

Troponin concentration

50000 ng/L

10000 ng/L

1000 ng/L

100 ng/L

50 ng/L

99<sup>th</sup> percentile

10 ng/L

5 ng/L

**Positive predictive value for MI**

**Very high**

**Very large MI, myocarditis**

**High**

**Large MI, myocarditis, stress cardiomyopathy, critical illness**

**Moderate**


**MI, myocarditis, stress cardiomyopathy, PE, shock, acute HF, subarachnoid hemorrhage**

**Low**

**MI, myocarditis, stress cardiomyopathy, chronic HF, PE, chronic kidney disease, shock, hypertensive crisis, subarachnoid hemorrhage**

**Stable angina, HF, LVH, subclinical heart disease; negative predictive value for MI ~95%**

**Healthy individuals; negative predictive value for MI ~99%**



# Myocardial Injury

(Elevated cardiac troponin value(s) >99<sup>th</sup> percentile)

## Rising and/or falling troponin: acute myocardial injury

- Evaluation**
- History and physical examination
  - Assess for myocardial ischemia:
    - Symptoms
    - New ECG changes
    - New wall motion abnormalities on imaging
    - Coronary occlusion at angiography

Ischemia present

Ischemia absent

- ### Myocardial Infarction
- **Type 1** Plaque rupture, ulceration, or dissection resulting in coronary thrombus
  - **Type 2** MI due to oxygen supply/demand mismatch
  - **Type 3** Sudden cardiac death secondary to MI
  - **Type 4** MI associated with PCI or stent thrombosis
  - **Type 5** MI associated with cardiac surgery

- ### Non-ischemic Myocardial Injury: Differential diagnosis
- | <u>Cardiovascular causes</u>   | <u>Non-cardiovascular causes</u>  |
|--|---|
| <ul style="list-style-type: none"><li>• Acute heart failure</li><li>• Pulmonary embolism</li><li>• Myocarditis</li><li>• Aortic dissection</li><li>• Cardiac surgery or procedures</li><li>• Hypertension</li><li>• Cardiac arrhythmias</li><li>• Acute valvular heart disease</li><li>• Takotsubo cardiomyopathy</li><li>• Cardiac contusions</li></ul> | <ul style="list-style-type: none"><li>• Acute renal failure</li><li>• Sepsis</li><li>• Anemia</li><li>• Hypotension</li><li>• Hypoxia</li><li>• Non-cardiac surgery</li><li>• Critical illness</li><li>• Rhabdomyolysis</li><li>• Drug induced</li><li>• Stroke and brain hemorrhage</li><li>• Extreme exertion</li></ul> |

## Stable but elevated troponin: chronic myocardial injury

- Evaluation**
- History and Physical Exam
  - Laboratory Data: creatinine/estimated glomerular filtration rate, complete blood count, natriuretic peptide. Consider C-reactive protein or erythrocyte sedimentation rate and/or d dimer.
  - Testing: ECG, TTE, consider cardiac magnetic resonance imaging

- ### Chronic Myocardial Injury: Differential diagnosis
- | <u>Cardiovascular causes</u>  | <u>Non-cardiovascular causes</u>   |
|---|--|
| <ul style="list-style-type: none"><li>• Chronic heart failure</li><li>• Infiltrative cardiomyopathy</li><li>• Hypertrophic cardiomyopathy</li><li>• Stable coronary artery disease</li><li>• Hypertension</li><li>• Valvular heart disease</li><li>• Persistent arrhythmias</li></ul> | <ul style="list-style-type: none"><li>• Chronic renal disease</li><li>• Pulmonary hypertension</li><li>• Diabetes Mellitus</li><li>• Drug induced</li><li>• Toxins</li></ul> |

Management depending on MI type

Evaluation and management depending on clinical scenario and cause of myocardial injury